医学综述
醫學綜述
의학종술
MEDICAL RECAPITULATE
2015年
12期
2281-2283
,共3页
胃癌%奥沙利铂%替吉奥%卡培他滨%不良反应%Karnofsky评分
胃癌%奧沙利鉑%替吉奧%卡培他濱%不良反應%Karnofsky評分
위암%오사리박%체길오%잡배타빈%불량반응%Karnofsky평분
Gastric cancer%Oxaliplatin%S-1%Capecitabine%Adverse reaction%Karnofsky score
目的：探讨奥沙利铂联合替吉奥对胃癌患者术后辅助化疗效果及不良反应的发生情况。方法将2009年9月至2011年9月枣阳市第一人民医院收治的60例胃癌术后患者依据随机数字表法分为两组：对照组（28例）给予奥沙利铂（130 mg／m2，静脉滴注，第1日）联合卡培他滨[1650 mg／（m2· d），口服，第1～14日]方案；观察组（32例）给予奥沙利铂联合替吉奥[80 mg／（m2· d），口服，第1～14日]方案。比较两组患者的临床疗效、治疗前后免疫功能相关指标水平变化、治疗前后Karnofsky评分、生活质量、3年生存率及不良反应发生情况。结果①观察组总缓解率为78.1％，显著高于对照组的60.7％（ P＜0.05）；②治疗后，两组患者IgG IgM、IgA均高于治疗前，且观察组 IgG、IgA高于对照组，差异均有统计学意义（均P＜0.01）；③治疗后两组患者的 Karnofsky评分均低于治疗前，差异有统计学意义（ P＜0.01）；④根据SF-36生活质量评价标准，观察组治疗后生活质量各项评分均显著高于对照组（P＜0.05）；⑤观察组1、2、3年生存率均显著高于对照组（P＜0.01）。⑥两组不良反应发生率比较差异无统计学意义（ P＞0.05）。结论与奥沙利铂联合替吉奥方案相比，奥沙利铂联合替吉奥治疗胃癌患者疗效更显著，且不良反应均可耐受。
目的：探討奧沙利鉑聯閤替吉奧對胃癌患者術後輔助化療效果及不良反應的髮生情況。方法將2009年9月至2011年9月棘暘市第一人民醫院收治的60例胃癌術後患者依據隨機數字錶法分為兩組：對照組（28例）給予奧沙利鉑（130 mg／m2，靜脈滴註，第1日）聯閤卡培他濱[1650 mg／（m2· d），口服，第1～14日]方案；觀察組（32例）給予奧沙利鉑聯閤替吉奧[80 mg／（m2· d），口服，第1～14日]方案。比較兩組患者的臨床療效、治療前後免疫功能相關指標水平變化、治療前後Karnofsky評分、生活質量、3年生存率及不良反應髮生情況。結果①觀察組總緩解率為78.1％，顯著高于對照組的60.7％（ P＜0.05）；②治療後，兩組患者IgG IgM、IgA均高于治療前，且觀察組 IgG、IgA高于對照組，差異均有統計學意義（均P＜0.01）；③治療後兩組患者的 Karnofsky評分均低于治療前，差異有統計學意義（ P＜0.01）；④根據SF-36生活質量評價標準，觀察組治療後生活質量各項評分均顯著高于對照組（P＜0.05）；⑤觀察組1、2、3年生存率均顯著高于對照組（P＜0.01）。⑥兩組不良反應髮生率比較差異無統計學意義（ P＞0.05）。結論與奧沙利鉑聯閤替吉奧方案相比，奧沙利鉑聯閤替吉奧治療胃癌患者療效更顯著，且不良反應均可耐受。
목적：탐토오사리박연합체길오대위암환자술후보조화료효과급불량반응적발생정황。방법장2009년9월지2011년9월조양시제일인민의원수치적60례위암술후환자의거수궤수자표법분위량조：대조조（28례）급여오사리박（130 mg／m2，정맥적주，제1일）연합잡배타빈[1650 mg／（m2· d），구복，제1～14일]방안；관찰조（32례）급여오사리박연합체길오[80 mg／（m2· d），구복，제1～14일]방안。비교량조환자적림상료효、치료전후면역공능상관지표수평변화、치료전후Karnofsky평분、생활질량、3년생존솔급불량반응발생정황。결과①관찰조총완해솔위78.1％，현저고우대조조적60.7％（ P＜0.05）；②치료후，량조환자IgG IgM、IgA균고우치료전，차관찰조 IgG、IgA고우대조조，차이균유통계학의의（균P＜0.01）；③치료후량조환자적 Karnofsky평분균저우치료전，차이유통계학의의（ P＜0.01）；④근거SF-36생활질량평개표준，관찰조치료후생활질량각항평분균현저고우대조조（P＜0.05）；⑤관찰조1、2、3년생존솔균현저고우대조조（P＜0.01）。⑥량조불량반응발생솔비교차이무통계학의의（ P＞0.05）。결론여오사리박연합체길오방안상비，오사리박연합체길오치료위암환자료효경현저，차불량반응균가내수。
Objective To investigate the effect and occurrence of adverse reactions of postoperative aux-iliary chemotherapy using oxaliplatin combined with S-1 for patients with gastric cancer.Methods A total of 60 patients after gastric cancer operation admitted in Zaoyang First People′s Hospital from Sep.2009 to Sep. 2011 were randomly divided into control group 28 cases and observation group 32 cases.Patients in the con-trol group were given oxaliplatin(130 mg/m2, iv.,d1) combined with capecitabine[1650 mg/(m2· d), oral,d1-14],and patients in the observation group were given oxaliplatin(130 mg/m2,iv,d1) combined with S-1[80 mg/(m2· d),oral,d1-14].The clinical efficacy,changes of immune function related indexes before and after treatment,Karnofsky scores before and after treatment,quality of life,3-year survival rate and incidence of adverse reactions of the two groups were compared.Results ①The total response rate of the observation group was 78.1%,which was significantly higher than the control group(60.71%)(P<0.05).②After treatment,levels of IgG,IgM,IgA in both groups were higher than those before treatment,and levels of IgG,IgA of the observation group were higher than those of the control group,the differences were statistically significant( P<0.01);③After treatment,Karnofsky scores of both groups were lower than those before treat-ment,the differences were statistically significant ( P<0.01 );④According to the SF-36 evaluation criteria of quality of life,quality of life scores in the observation group after treatment were significantly higher than those in the control group(P<0.05);⑤1,2,3-year survival rates of the observation group were significantly higher than those of the control group (P<0.01).⑥The incidence of adverse reactions of two groups was no statistically significant (P >0.05).Conclusion Compared with oxaliplatin combined with capecitabine, oxaliplatin combined with S-1 has more significant effect on gastric cancer,with tolerable adverse reactions.
